Grufity logoGrufity logo

Organovo Holdings Inc Stock Research

ONVO

1.98USD+0.07(+3.66%)Delayed

Market Summary

USD1.98+0.07
Delayed
3.66%

ONVO Stock Price

ONVO RSI Chart

ONVO Valuation

Market Cap

17.3M

Price/Earnings (Trailing)

-1.47

Price/Sales (Trailing)

58.56

Price/Free Cashflow

-1.8

ONVO Price/Sales (Trailing)

ONVO Profitability

Return on Equity

-52.54%

Return on Assets

-46.7%

Free Cashflow Yield

-55.49%

ONVO Fundamentals

ONVO Revenue

Revenue Y/Y

-82.53%

Revenue Q/Q

70.13%

ONVO Earnings

Earnings (TTM)

-11.7M

Earnings Y/Y

6.74%

Earnings Q/Q

1.72%

Price Action

52 Week Range

1.374.11
(Low)(High)

Last 7 days

-8.6%

Last 30 days

-10.3%

Last 90 days

7.3%

Trailing 12 Months

-50.1%

ONVO Financial Health

Current Ratio

15.71

ONVO Investor Care

Shares Dilution (1Y)

0.10%

Diluted EPS (TTM)

-1.34

Peers (Alternatives to Organovo Holdings)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
99.6B
27.3B
-8.96% 41.01%
21.68
3.65
-0.09% -26.23%
58.4B
19.3B
-12.76% 1.00%
6.99
3.03
4.29% -31.47%
16.5B
3.4B
-9.50% -1.15%
48.37
4.85
13.67% -64.09%
11.8B
2.1B
-1.61% 11.81%
-18.88
5.65
17.95% -4.68%
MID-CAP
5.7B
1.6B
0.62% -12.32%
31.44
3.56
12.27% -21.11%
3.2B
108.5M
-21.10% -19.55%
-9.78
29.38
122.90% -12.19%
2.0B
-
-14.81% 192.41%
-9.94
-
- -44.28%
SMALL-CAP
1.2B
-
-5.15% -45.48%
-3.14
-
- -15.67%
615.9M
130.5M
-14.48% 101.94%
-8.76
4.72
90.44% 5.49%
513.7M
2.0B
-39.67% -92.01%
-0.78
0.26
72.89% 62.27%
276.2M
450.9M
-22.02% -71.01%
17.79
0.61
-3.52% -83.51%
143.9M
60.3M
-71.28% -88.95%
-0.29
2.39
17.51% -38.93%
98.8M
228.0M
-44.24% -11.03%
49.4K
0.43
-9.92% 100.01%
56.8M
-
0.97% -84.15%
-0.52
-
- -182.89%
17.3M
-
-10.33% -50.13%
-1.47
58.56
-83.33% 3.48%

Financials for Organovo Holdings

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q12021Q42020Q1
RevenueNaN%1,5001,8482,196
Operating Expenses-0.1%13,54713,56012,755--
  S&GA Expenses-2.9%9,0029,2719,6599,306-
  R&D Expenses6.0%4,5714,3123,3202,858-
Costs and Expenses-12,979----
EBITDA--2.90----
EBITDA Margin-0.00*----
EBT Margin--0.06*----
Net Income2.0%-11,711-11,947-11,448-12,133-
Net Income Margin-408.2%-38.79*-7.63*---
Free Cahsflow3.5%-9,575-9,923-8,862--
Balance Sheet
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-10.1%25,07927,91030,54633,29635,095
  Current Assets-11.3%21,61424,35726,90929,53331,171
    Cash Equivalents52.3%20,20013,26515,56828,67530,269
  Net PPE-2.1%742758690662652
Liabilities-3.9%2,7902,9042,8923,0873,802
  Current Liabilities-0.9%1,3761,3891,2821,3832,006
Shareholder's Equity-10.9%22,28925,00627,65430,20931,293
  Retained Earnings-1.0%-317,539-314,300-310,954-307,739-305,800
  Additional Paid-In Capital0.2%339,817339,273338,600337,940337,113
Accumulated Depreciation-1,071----
Shares Outstanding0.0%8,7158,7138,7128,7118,706
Cashflow (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations2.7%-9,288-9,544-9,487-8,500-9,026
  Share Based Compensation-1.6%2,7042,7482,5012,2561,716
Cashflow From Investing92.2%-857-10,965-10,908-409-467
Cashflow From Financing100.0%0.00-1.00-46.0020520,958
  Buy BacksNaN%0.000.00---

Risks for ONVO

What is the probability of a big loss on ONVO?

100%


Probability that Organovo Holdings stock will be more than 20% underwater in next one year

100%


Probability that Organovo Holdings stock will be more than 30% underwater in next one year.

99.6%


Probability that Organovo Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ONVO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Organovo Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for ONVO

Cumulative Returns on ONVO

-31.0%


10-Year Cumulative Returns

-36.2%


7-Year Cumulative Returns

-38.7%


5-Year Cumulative Returns

-26.7%


3-Year Cumulative Returns

What are the long-term rolling returns for ONVO?

FIve years rolling returns for Organovo Holdings.

Annualized Returns

Which funds bought or sold ONVO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-06
Rockefeller Capital Management L.P.
new
-
-
-
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
unchanged
-
173
173
-%
2023-02-15
Steward Partners Investment Advisory, LLC
unchanged
-
7.00
7.00
-%
2023-02-15
Virtu Financial LLC
sold off
-100
-30,000
-
-%
2023-02-14
ROYAL BANK OF CANADA
sold off
-100
-
-
-%
2023-02-14
MILLENNIUM MANAGEMENT LLC
sold off
-100
-50,000
-
-%
2023-02-14
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
0.73
-31,046
71,954
-%
2023-02-14
NewEdge Advisors, LLC
new
-
15.00
15.00
-%
2023-02-14
FIRST MANHATTAN CO
unchanged
-
35.00
35.00
-%
2023-02-14
MORGAN STANLEY
reduced
-0.51
-22,523
47,477
-%

1–10 of 43

Latest Funds Activity

Are funds buying ONVO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ONVO
No. of Funds

Organovo Holdings News

Defense World

Organovo (NASDAQ:ONVO) Now Covered by Analysts at ....

Defense World,
3 days ago

Seeking Alpha

Value the Markets

Schedule 13G FIlings of Organovo Holdings

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
5.21%
454,752
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
5.50%
478,570
SC 13G/A
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
5.49%
478,570
SC 13G/A
Mar 10, 2021
ark investment management llc
9.48%
674,454
SC 13G/A
Feb 16, 2021
ark investment management llc
20.86%
1,404,620
SC 13G/A
Feb 11, 2021
renaissance technologies llc
5.36%
381,353
SC 13G/A
Feb 11, 2021
nikko asset management americas, inc.
7.11%
478,570
SC 13G/A
Feb 05, 2021
sumitomo mitsui trust holdings, inc.
7.11%
478,570
SC 13G/A
Oct 09, 2020
ark investment management llc
21.78%
1,422,394
SC 13G/A
Feb 14, 2020
ark investment management llc
14.95%
19,499,439
SC 13G/A

ONVO Fair Value

Recent SEC filings of Organovo Holdings

View All Filings
Date Filed Form Type Document
Mar 15, 2023
8-K
Current Report
Feb 10, 2023
SC 13G/A
Major Ownership Report
Feb 09, 2023
10-Q
Quarterly Report
Feb 03, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for ONVO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-10
Joshi Vaidehi
acquired
-
-
19,607
-
2022-11-10
Gobel David
acquired
-
-
19,607
-
2022-11-10
Milhous Alison Tjosvold
acquired
-
-
19,607
-
2022-11-10
Cohen Douglas Jay
acquired
-
-
19,607
-
2022-11-10
STERN ADAM K
acquired
-
-
19,607
-
2022-11-10
Murphy Keith
acquired
-
-
19,607
executive chairman
2021-11-19
Gobel David
sold
-766
5.285
-145
-
2021-08-17
Cohen Douglas Jay
bought
6,719
6.7198
1,000
-
2021-08-17
Cohen Douglas Jay
bought
58,838
6.7244
8,750
-
2021-08-17
Cohen Douglas Jay
bought
6,737
6.7379
1,000
-

1–10 of 36

Keith Murphy
9
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

ONVO Income Statement

2022-09-30
Unaudited Condensed Consolidated Statements of Operations and Other Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues    
Total Revenues$ 77$ 0$ 77$ 0
Revenue From Contract With Customer Product And Service [Extensible List]us-gaap:RoyaltyMemberus-gaap:RoyaltyMemberus-gaap:RoyaltyMemberus-gaap:RoyaltyMember
Research and development expenses$ 1,231$ 679$ 2,251$ 1,259
Selling, general and administrative expenses2,2002,8284,4194,807
Total costs and expenses3,4313,5076,6706,066
Loss from Operations(3,354)(3,507)(6,593)(6,066)
Other Income (Expense)    
Loss on investment in equity securities(70)0(75)0
Interest income10321344
Other income00025
Total Other Income3325929
Income Tax Expense00(2)0
Net Loss$ (3,321)$ (3,505)$ (6,536)$ (6,037)
Net loss per common share basic$ (0.38)$ (0.40)$ (0.75)$ (0.69)
Net loss per common share diluted$ (0.38)$ (0.40)$ (0.75)$ (0.69)
Weighted average shares used in computing net loss per common share basic8,712,2848,705,3278,711,6308,701,029
Weighted average shares used in computing net loss per common share diluted8,712,2848,705,3278,711,6308,701,029
Comprehensive Loss:    
Net loss$ (3,321)$ (3,505)$ (6,536)$ (6,037)
Comprehensive loss$ (3,321)$ (3,505)$ (6,536)$ (6,037)

ONVO Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Mar. 31, 2022
Current Assets  
Cash and cash equivalents$ 13,265$ 28,675
Short-term investments9,9550
Investment in equity securities6180
Prepaid expenses and other current assets519858
Total current assets24,35729,533
Fixed assets, net758662
Restricted cash143143
Operating lease right-of-use assets1,9582,153
Prepaid expenses and other assets, net694805
Total assets27,91033,296
Current Liabilities  
Accounts payable441415
Accrued expenses462489
Operating lease liability, current portion486479
Total current liabilities1,3891,383
Operating lease liability, net of current portion1,5151,704
Total liabilities2,9043,087
Stockholders’ Equity  
Common stock, $0.001 par value; 200,000,000 shares authorized, 8,713,268 and 8,710,627 shares issued and outstanding at September 30, 2022 and March 31, 2022, respectively99
Additional paid-in capital339,273337,940
Accumulated deficit(314,275)(307,739)
Treasury stock, 46 shares at cost(1)(1)
Total stockholders’ equity25,00630,209
Total Liabilities and Stockholders’ Equity$ 27,910$ 33,296